CASI Pharmaceuticals, Inc. Intellectual Property Contracts & Agreements

7 Contracts & Agreements
Browse by Subcategory
Recent Contracts
Category
Company
Industry
Jur. Jurisdiction
Filed
License and Development Agreement for CB-5339 by and between Cleave Therapeutics, Inc. and CASI Pharmaceuticals, Inc. dated March 5, 2021
License Agreements
CASI Pharmaceuticals, Inc.
Biotechnology
MD
2021
License Agreement, dated as of September 17, 2014, by and between CASI Pharmaceuticals, Inc. and Talon Therapeutics, Inc
License Agreements
CASI Pharmaceuticals, Inc.
Biotechnology
NY
2021
License Agreement, dated as of September 17, 2014, by and between CASI Pharmaceuticals, Inc. and Spectrum Pharmaceuticals Cayman, L.P
License Agreements
CASI Pharmaceuticals, Inc.
Biotechnology
NY
2021
License Agreement, dated as of September 17, 2014, by and between CASI Pharmaceuticals, Inc. and Spectrum Pharmaceuticals, Inc
License Agreements
CASI Pharmaceuticals, Inc.
Biotechnology
CA
2021
Supplementary Agreement to the Exclusive License Agreement effective as of September 29, 2020
License Agreements
CASI Pharmaceuticals, Inc.
Biotechnology
2020
Exclusive License Agreement by and between CASI Pharmaceuticals, Inc. and Juventas Cell Therapy Ltd. effective June 15, 2019
License Agreements
CASI Pharmaceuticals, Inc.
Biotechnology
MD
2019
License Agreement By and between EntreMed, Inc. and Celgene Corporation.
License Agreements
CASI Pharmaceuticals, Inc.
Biotechnology
DE
2005